Skip to main content
SpringerLink
Log in
Book cover

Postmenopausal Diseases and Disorders pp 165–185Cite as

Screening and Management of Female Sexual Dysfunction During the Second Half of Life

  • Chapter
  • First Online:

Abstract

Female sexual dysfunction (FSD) includes different disorders that are highly prevalent in perimenopausal and older women which require precise diagnosis and management. Screening of FSD should be based on clinical history and the use of screening tools such as the 14-item Changes in Sexual Functioning Questionnaire, the 19-item Female Sexual Function Index (FSFI-19) and its short version (FSFI-6), or the Decreased Sexual Desire Screener. The clinical exam should include the assessment of menopausal symptoms, vulvovaginal atrophy, and comorbidity including pelvic floor disorders, endocrine disorders, depressive symptoms, cancer diseases, and chronic medication use that may interfere with sexuality. The management of genito-pelvic pain/penetration disorders includes the appropriate treatment of the genitourinary syndrome of menopause, urinary incontinence, and pelvic floor disorders with appropriate selection for surgery and/or other treatments. The management of female sexual interest/arousal disorder (also known as hypoactive sexual desire disorder) may include systemic or topical steroid hormone therapy, including dehydroepiandrosterone sulfate, central-acting agents (flibanserin, bupropion, bremelanotide), and/or natural remedies (Tribulus terrestris, Trigonella foenum-graecum). Female orgasmic disorder may be managed by conductual methods and/or drugs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chedraui P, Pérez-López FR. Assessing sexual problems in women at midlife using the short version of the female sexual function index. Maturitas. 2015;82:298–302.

    Article  Google Scholar 

  2. Pérez-López FR, Fernández-Alonso AM, Trabalón Pastor M, Vara C, Chedraui P. Assessment of sexual function with the 6-item female sex function index and related factors in mid-aged sexually active Spanish women. Menopause. 2012;19:1224–30.

    Article  PubMed  Google Scholar 

  3. Chedraui P, Pérez-López FR, Blümel JE, Hidalgo L, Barriga J. Hyperglycemia in postmenopausal women screened for the metabolic syndrome is associated to increased sexual complaints. Gynecol Endocrinol. 2010;26:86–92.

    Article  CAS  PubMed  Google Scholar 

  4. McCool-Myers M, Theurich M, Zuelke A, Knuettel H, Apfelbacher C. Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms. BMC Womens Health. 2018;18:108.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chedraui P, Pérez-López FR, San Miguel G, Avila C. Assessment of sexuality among middle-aged women using the female sexual function index. Climacteric. 2009;12:213–21.

    Article  CAS  PubMed  Google Scholar 

  6. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a primary care setting: a survey finding. J Sex Med. 2010;7:3080–7.

    Article  PubMed  Google Scholar 

  7. McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Lewis R, Segraves RT. Definitions of sexual dysfunctions in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med. 2016;13:135–43.

    Article  PubMed  Google Scholar 

  8. World Health Organization. International Classification Diseases 11. http://www.who.int/classifications/icd/en/. Accessed 11 Aug 2018.

  9. American Psychiatric Association. DSM-5: diagnostic and statistical manual for mental disorders. 5th ed. Washington, DC: American Psychiatric Press; 2013.

    Book  Google Scholar 

  10. Kingsberg SA, Althof S, Simon JA, Bradford A, Bitzer J, Carvalho J, Flynn KE, Nappi RE, Reese JB, Rezaee RL, Schover L, Shifrin JL. Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14. J Sex Med. 2017;14:1463–91. Erratum in: J Sex Med. 2018;15:270.

    Article  PubMed  Google Scholar 

  11. Szwabo PA. Counseling about sexuality in the older person. Clin Geriatr Med. 2003;19:595–604.

    Article  PubMed  Google Scholar 

  12. Cuerva MJ, González D, Canals M, Otero B, Espinosa JA, Molero F, Senturk LM, Mendoza N, SMS Young Experts Group. The sexual health approach in postmenopause: the five-minutes study. Maturitas. 2018;108:31–6.

    Article  PubMed  Google Scholar 

  13. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731–45.

    CAS  PubMed  Google Scholar 

  14. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14). J Sex Marital Ther. 2006;32:43–52.

    Article  PubMed  Google Scholar 

  15. Ornat L, Martínez-Dearth R, Muñoz A, Franco P, Alonso B, Tajada M, Pérez-López FR. Sexual function, satisfaction with life and menopausal symptoms in middle-aged women. Maturitas. 2013;75:261–9.

    Article  PubMed  Google Scholar 

  16. Llaneza P, Fernández-Iñarrea JM, Arnott B, García-Portilla MP, Chedraui P, Pérez-López FR. Sexual function assessment in postmenopausal women with the 14-item changes in sexual functioning questionnaire. J Sex Med. 2011;8:2144–51.

    Article  PubMed  Google Scholar 

  17. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.

    Article  CAS  PubMed  Google Scholar 

  18. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.

    Article  PubMed  Google Scholar 

  19. Burri A, Hilpert P, Spector T. Longitudinal evaluation of sexual function in a cohort of pre- and postmenopausal women. J Sex Med. 2015;12:1427–35.

    Article  PubMed  Google Scholar 

  20. Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the Female Sexual Function Index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010;7:1139–46.

    Article  PubMed  Google Scholar 

  21. Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D’Agostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6:730–8.

    Article  PubMed  Google Scholar 

  22. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92:114–28.

    Article  PubMed  Google Scholar 

  23. Clayton AH, Goldstein I, Kim NN, Althof SE, Faubion SS, Faught BM, Parish SJ, Simon JA, Vignozzi L, Christiansen K, Davis SR, Freedman MA, Kingsberg SA, Kirana PS, Larkin L, McCabe M, Sadovsky R. The International Society for the Study of Women’s Sexual Health process of Care for Management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93:467–87.

    Article  PubMed  Google Scholar 

  24. Shindel AW, Rowen TA, Lin TC, Li CS, Robertson PA, Breyer BN. An internet survey of demographic and health factors associated with risk of sexual dysfunction in women who have sex with women. J Sex Med. 2012;9:1261–71.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Woods NF, Mitchell ES. Consequences of incontinence for women during the menopausal transition and early postmenopause: observations from the Seattle midlife Women’s health study. Menopause. 2013;20:915–21.

    Article  PubMed  Google Scholar 

  26. Rees M, Pérez-López FR, Ceasu I, Depypere H, Erel T, Lambrinoudaki I, Schenck-Gustafsson K, Simoncini T, van der Schouw Y, Tremollieres F. EMAS. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas. 2012;73:171–4.

    Article  PubMed  Google Scholar 

  27. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.

    Google Scholar 

  28. Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights Reprod Health. 2014;8:23–30.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the vaginal health: insights, views & attitudes survey. Menopause. 2013;20:1043–8.

    Article  PubMed  Google Scholar 

  30. Fernández-Alonso AM, Alcaide Torres J, Fernández Alonso IM, Chedraui P, Pérez-López FR. Application of the 21-items vulvovaginal symptoms questionnaire in postmenopausal Spanish women. Menopause. 2017;24:1295–301.

    Article  PubMed  Google Scholar 

  31. Gracia CR, Sammel MD, Freeman EW, Liu L, Hollander L, Nelson DB. Predictors of decreased libido in women during the late reproductive years. Menopause. 2004;11:144–50.

    Article  PubMed  Google Scholar 

  32. Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24:452–61.

    Article  PubMed  Google Scholar 

  33. Ke Y, Bélanger A, Simard JN, Gonthier R, Martel C, Vaillancourt M, Labrie F. Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy. Menopause. 2018;25:293–300.

    Article  PubMed  Google Scholar 

  34. Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and female sexual function and dysfunction findings from the fourth international consultation of sexual medicine. J Sex Med. 2016;13:168–78.

    Article  PubMed  Google Scholar 

  35. Shatkin-Margolis A, Pauls RN. Sexual function after prolapse repair. Curr Opin Obstet Gynecol. 2017;29:343–8.

    Article  PubMed  Google Scholar 

  36. Sayed Ahmed WA, Kishk EA, Farhan RI, Khamees RE. Female sexual function following different degrees of perineal tears. Int Urogynecol J. 2017;28:917–92.

    Article  PubMed  Google Scholar 

  37. Karbage SA, Santos ZM, Frota MA, de Moura HJ, Vasconcelos CT, Neto JA, Bezerra LR. Quality of life of Brazilian women with urinary incontinence and the impact on their sexual function. Eur J Obstet Gynecol Reprod Biol. 2016;201:56–60.

    Article  PubMed  Google Scholar 

  38. Salama S, Boitrelle F, Gauquelin A, Malagrida L, Thiounn N, Desvaux P. Nature and origin of “squirting” in female sexuality. J Sex Med. 2015;12:661–6.

    Article  PubMed  Google Scholar 

  39. Jha S, Ammenbal M, Metwally M. Impact of incontinence surgery on sexual function: a systematic review and metaanalysis. J Sex Med. 2012;9:34–43.

    Article  PubMed  Google Scholar 

  40. Su CC, Sun BY, Jiann BP. Association of urinary incontinence and sexual function in women. Int J Urol. 2015;22:109–13.

    Article  PubMed  Google Scholar 

  41. Hunter MM, Nakagawa S, Van Den Eeden SK, Kuppermann M, Huang AJ. Predictors of impact of vaginal symptoms in postmenopausal women. Menopause. 2016;23:40–6.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Lester RA, Protto RA, Sadownik LA. Provoked vestibulodynia and the health care implications of comorbid pain conditions. J Obstet Gynaecol Can. 2015;37:995–1005.

    Article  PubMed  Google Scholar 

  43. Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B. Sexual function and depressive symptoms in young women with thyroid autoimmunity and subclinical hypothyroidism. Clin Endocrinol. 2016;84:925–31.

    Article  CAS  Google Scholar 

  44. Oppo A, Franceschi E, Atzeni F, Taberlet A, Mariotti S. Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function. J Endocrinol Investig. 2011;34:449–53.

    Article  CAS  Google Scholar 

  45. Pasquali D, Maiorino MI, Renzullo A, Bellastella G, Accardo G, Esposito D, Barbato F, Esposito K. Female sexual dysfunction in women with thyroid disorders. J Endocrinol Investig. 2013;36:729–33.

    Article  CAS  Google Scholar 

  46. Janssen OE, Hahn S, Tan S, Benson S, Elsenbruch S. Mood and sexual function in polycystic ovary syndrome. Semin Reprod Med. 2008;26:45–52.

    Article  PubMed  Google Scholar 

  47. Benetti-Pinto CL, Ferreira SR, Antunes A Jr, Yela DA. The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2015;291:451–5.

    Article  PubMed  Google Scholar 

  48. Nasiri Amiri F, Ramezani Tehrani F, Esmailzadeh S, Tohidi M, Azizi F, Basirat Z. Sexual function in women with polycystic ovary syndrome and their hormonal and clinical correlations. Int J Impot Res. 2018;30:54–61.

    Article  CAS  PubMed  Google Scholar 

  49. Llaneza P, García-Portilla MP, Llaneza-Suárez D, Armott B, Pérez-López FR. Depressive disorders and the menopause transition. Maturitas. 2012;71:120–30.

    Article  PubMed  Google Scholar 

  50. Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med. 2012;9:1497–507.

    Article  PubMed  Google Scholar 

  51. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf. 2014;13:1361–74.

    Article  CAS  PubMed  Google Scholar 

  52. Clayton AH, Maserejian NN, Connor MK, Huang L, Heiman JR, Rosen RC. Depression in premenopausal women with HSDD: baseline findings from the HSDD registry for women. Psychosom Med. 2012;74:305–11.

    Article  PubMed  Google Scholar 

  53. Alicikus ZA, Gorken JB, Sen RC, Kentli S, Kinay M, Alanyali H, Harmancioglu O. Psychosexual and body image aspects of quality of life in Turkish breast cancer patients: a comparison of breast conserving treatment and mastectomy. Tumori. 2009;95:212–8.

    Article  PubMed  Google Scholar 

  54. Stan D, Loprinzi CL, Ruddy KJ. Breast cancer survivorship issues. Hematol Oncol Clin North Am. 2013;27:805–27.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med. 2011;8:294–302.

    Article  PubMed  Google Scholar 

  56. Fobair P, Spiegel D. Concerns about sexuality after breast cancer. Cancer J. 2009;15:19–26.

    Article  PubMed  Google Scholar 

  57. Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28:418–23.

    Article  PubMed  Google Scholar 

  58. Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc. 2016;91:1280–6.

    Article  CAS  PubMed  Google Scholar 

  59. Coupland C, Morriss R, Arthur A, Moore M, Hill T, Hippisley-Cox J. Safety of antidepressants in adults aged under 65: protocol for a cohort study using a large primary care database. BMC Psychiatry. 2013;13:135.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Ishak WW, Christensen S, Sayer G, Ha K, Li N, Miller J, Nguyen JM, Cohen RM. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR∗D study. J Clin Psychiatry. 2013;74:256–61.

    Article  CAS  PubMed  Google Scholar 

  61. Doumas M, Tsiodras S, Tsakiris A, Douma S, Chounta A, Papadopoulos A, Kanellakopoulou K, Giamarellou H. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24:2387–92.

    Article  CAS  PubMed  Google Scholar 

  62. Spatz ES, Canavan ME, Desai MM, Krumholz HM, Lindau ST. Sexual activity and function among middle-aged and older men and women with hypertension. J Hypertens. 2013;31:1096–105.

    Article  CAS  PubMed  Google Scholar 

  63. Thomas HN, Evans GW, Berlowitz DR, Chertow GM, Conroy MB, Foy CG, Glasser SP, Lewis CE, Riley WT, Russell L, Williams O, Hess R, SPRINT Study Group. Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT). J Hypertens. 2016;34:1224–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Bitzer J, Platano G, Tschudin S, Alder J. Sexual counseling in elderly couples. J Sex Med. 2008;5:2027–43.

    Article  PubMed  Google Scholar 

  65. Annon JS. The PLISSIT model: a proposed conceptual scheme for the behavioral treatment of sexual problems. J Sex Educ Ther. 1976;2:1–15.

    Article  Google Scholar 

  66. Herbenick D, Fu T-C, Arter J, Sanders SA, Dodge B. Women’s experiences with genital touching, sexual pleasure, and orgasm: results from a U.S. probability sample of women ages 18 to 94. J Sex Marital Ther. 2018;44:201–12.

    Article  PubMed  Google Scholar 

  67. Steinke EE. Sexuality and chronic illness. J Gerontol Nurs. 2013;39:18–27.

    Article  PubMed  Google Scholar 

  68. Steinke E, Jaarsma T. Sexual counseling and cardiovascular disease: practical approaches. Asian J Androl. 2015;17:32.

    Article  PubMed  Google Scholar 

  69. Sarwer DB, Durlak JA. A field trial of the effectiveness of behavioral treatment for sexual dysfunctions. J Sex Marital Ther. 1997;23:87–97.

    Article  CAS  PubMed  Google Scholar 

  70. Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav. 2013;42:915–33.

    Article  PubMed  Google Scholar 

  71. Bouman WP. Principles and practice of sex therapy. Sex Relation Ther. 2008;23:95–101.

    Article  Google Scholar 

  72. Kim H-K, Kang S-Y, Chung Y-J, Kim J-H, Kim M-R. The recent review of the genitourinary syndrome of menopause. J Menopausal Med. 2015;21:65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–8.

    Article  PubMed  Google Scholar 

  74. Farrell AE. Genitourinary syndrome of menopause. Aust Fam Physician. 2017;46:481–4.

    Google Scholar 

  75. Vieira-Baptista P, Marchitelli C, Haefner HK, Donders G, Pérez-López F. Deconstructing the genitourinary syndrome of menopause. Int Urogynecol J. 2017;28:675–9.

    Article  PubMed  Google Scholar 

  76. Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24:1246–56.

    Article  PubMed  Google Scholar 

  77. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18:226–32.

    Article  CAS  PubMed  Google Scholar 

  78. Lowenstein L, Gamble T, Sanses TV, van Raalte H, Carberry C, Jakus S, Kambiss S, McAchran S, Pham T, Aschkenazi S, Hoskey K, Kenton K, Fellow’s Pelvic Research Network. Sexual function is related to body image perception in women with pelvic organ prolapse. J Sex Med. 2009;6:2286–91.

    Article  PubMed  Google Scholar 

  79. Yount SM. The impact of pelvic floor disorders and pelvic surgery on women’s sexual satisfaction and function. J Midwifery Womens Health. 2013;58:538–45.

    Article  PubMed  Google Scholar 

  80. Uçar MG, İlhan TT, Şanlıkan F, Çelik Ç. Sexual functioning before and after vaginal hysterectomy to treat pelvic organ prolapse and the effects of vaginal cuff closure techniques: a prospective randomised study. Eur J Obstet Gynecol Reprod Biol. 2016;206:1–5.

    Article  PubMed  Google Scholar 

  81. Barski D, Otto T, Gerullis H. Systematic review and classification of complications after anterior, posterior, apical, and total vaginal mesh implantation for prolapse repair. Surg Technol Int. 2014;24:217–24.

    PubMed  Google Scholar 

  82. Mota RL. Female urinary incontinence and sexuality. Int Braz J Urol. 2017;43:20–8.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Lee UJ, Kerkhof MH, van Leijsen SA, Heesakkers JP. Obesity and pelvic organ prolapse. Curr Opin Urol. 2017;27:428–34.

    Article  PubMed  Google Scholar 

  84. Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357:762–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause. 2005;12:497–511.

    Article  Google Scholar 

  86. Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet (London, England). 2007;369:597–611.

    Article  CAS  Google Scholar 

  87. Basson R. Review: testosterone therapy for reduced libido in women. Ther Adv Endocrinol Metab. 2010;1:155–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Gass ML, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, Lane DS, LaValleur J, Ockene JK, Mouton CP, Barad DH. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women’s Health Initiative. Menopause. 2011;18:1160–71.

    Article  PubMed  Google Scholar 

  89. Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas. 2009;63:63–6.

    Article  CAS  PubMed  Google Scholar 

  90. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9:1134–48.

    Article  CAS  PubMed  Google Scholar 

  91. NICE guideline [NG23]. Menopause: diagnosis and management. 2015. https://www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed 12 Aug 2018.

  92. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab. 2011;96:1642–53.

    Article  CAS  PubMed  Google Scholar 

  93. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;(1):CD011066.

    Google Scholar 

  94. Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric. 2001;4:314–9.

    Article  CAS  PubMed  Google Scholar 

  95. Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, Norman RJ, Mulder RJ, Davis SR, LISA Study Investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med. 2008;5:646–56.

    Article  CAS  PubMed  Google Scholar 

  96. Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecol Endocrinol. 2010;26:804–14.

    Article  CAS  PubMed  Google Scholar 

  97. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16:923–31.

    Article  PubMed  Google Scholar 

  98. Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, Lehrfeld K, Lee L, Kim MJ, Slagle AF, Beitz J. FDA approval of flibanserin—treating hypoactive sexual desire disorder. N Engl J Med. 2016;374:101–4.

    Article  PubMed  Google Scholar 

  99. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21:633–40.

    Article  PubMed  Google Scholar 

  100. Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study. J Sex Med. 2017;14:834–42.

    Article  PubMed  Google Scholar 

  101. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176:453–62.

    Article  PubMed  Google Scholar 

  102. Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106:832–9.

    Article  CAS  PubMed  Google Scholar 

  103. Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (London). 2016;12:325–37.

    Article  CAS  Google Scholar 

  104. Akhtari E, Raisi F, Keshavarz M, Hosseini H, Sohrabvand F, Bioos S, Kamalinejad M, Ghobadi A. Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo—controlled study. Daru. 2014;22:40.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Steels E, Steele ML, Harold M, Coulson S. Efficacy of a proprietary Trigonella foenum-graecum L. de-husked seed extract in reducing menopausal symptoms in otherwise healthy women: a double-blind, randomized, placebo-controlled study. Phytother Res. 2017;31:1316–22.

    Article  CAS  PubMed  Google Scholar 

  106. LoPiccolo J, Lobitz WC. The role of masturbation in the treatment of orgasmic dysfunction. Arch Sex Behav. 1972;2:163–71.

    Article  CAS  PubMed  Google Scholar 

  107. Andersen BL. A comparison of systematic desensitization and directed masturbation in the treatment of primary orgasmic dysfunction in females. J Consult Clin Psychol. 1981;49:568–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Eichel EW, Eichel JD, Kule S. The technique of coital alignment and its relation to female orgasmic response and simultaneous orgasm. J Sex Marital Ther. 1988;14:129–41.

    Article  CAS  PubMed  Google Scholar 

  109. Hurlbert DF, Apt C. The coital alignment technique and directed masturbation: a comparative study on female orgasm. J Sex Marital Ther. 1995;21:21–9.

    Article  CAS  PubMed  Google Scholar 

  110. Marcus BS. Changes in a woman’s sexual experience and expectations following the introduction of electric vibrator assistance. J Sex Med. 2011;8:3398–406.

    Article  PubMed  Google Scholar 

  111. Herbenick D, Barnhart KJ, Beavers K, Benge S. Vibrators and other sex toys are commonly recommended to patients, but does size matter? Dimensions of commonly sold products. J Sex Med. 2015;12:641–5.

    Article  PubMed  Google Scholar 

  112. Chivers ML, Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med. 2010;7:858–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Competing Interest

None to declare.

Funding: None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Hospital Torrecárdenas, Almería, Spain

    Ana M. Fernández-Alonso

  2. Department of Obstetrics and Gynecology, Hospital Universitario La Paz, Madrid, Spain

    Marcos J. Cuerva

  3. Instituto de Investigación e Innovación en Salud Integral, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador

    Peter Chedraui

  4. Department of Obstetrics and Gynecology, University of Zaragoza Facultad de Medicina, Zaragoza, Spain

    Faustino R. Pérez-López

Authors
  1. Ana M. Fernández-Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcos J. Cuerva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Chedraui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Faustino R. Pérez-López
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Zaragoza Facultad de Medicina, Zaragoza, Spain

    Faustino R. Pérez-López

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fernández-Alonso, A.M., Cuerva, M.J., Chedraui, P., Pérez-López, F.R. (2019). Screening and Management of Female Sexual Dysfunction During the Second Half of Life. In: Pérez-López, F. (eds) Postmenopausal Diseases and Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-13936-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-13936-0_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-13935-3

  • Online ISBN: 978-3-030-13936-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation